About EDIT

Founded: 2013
Employees: 87
CEO: Gilmore O’Neill
WebsiteView website: www.editasmedicine.com

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Recent EDIT News & Updates

Announcement • Sep 09

Editas Medicine, Inc. Announces Appointment of Daniel Ory, M.D. as Chief Medical Officer, Effective September 8, 2026

Editas Medicine, Inc. announced the appointment of Daniel Ory, M.D., as Chief Medical Officer, effective September 8, 2026. Dr. Ory has more than 25 years of experience spanning biotechnology leadership, cardiovascular medicine, and the development of genetic medicines. Dr. Ory will oversee the company's clinical development strategy and operations as Editas advances EDIT-401, its lead in vivo development candidate for the potential treatment of hyperlipidemia, toward the clinic, while supporting the progression of the company's broader pipeline. Prior to joining Editas, Dr. Ory served as Chief Medical Officer at Arbor Biotechnologies, where he oversaw the global clinical trial for the company's lead in vivo gene editing program. Previously, he served as Chief Medical Officer at Casma Therapeutics, leading clinical development programs focused on rare genetic and neurodegenerative diseases. Before joining industry, Dr. Ory spent more than two decades at Washington University School of Medicine in St. Louis, where he served as the Alan A. and Edith L. Wolff Professor of Cardiology and conducted research in cholesterol metabolism and Niemann-Pick disease type C (NPC), helping advance the understanding of cholesterol homeostasis and its role in cardiovascular disease. Dr. Ory was scientific co-founder of Vtesse Therapeutics, a rare disease company. Clinically, Dr. Ory’s practice was focused on preventive and diagnostic cardiology, specializing in cardiovascular risk assessment and the application of stress echocardiography and nuclear perfusion imaging to guide the evaluation and management of patients at risk for coronary artery disease. During his academic career, he authored more than 160 peer-reviewed publications and is an inventor on numerous patents related to cardiovascular and rare disease research. He was elected a Fellow of the American Association for the Advancement of Science (AAAS) and is a member of both the American Society for Clinical Investigation (ASCI) and the Association of American Physicians (AAP). Dr. Ory received an A.B. from Harvard College and an M.D. from Harvard Medical School. He completed postdoctoral training at the Whitehead Institute at MIT, an internal medicine residency at Brigham and Women's Hospital, and a fellowship in cardiology at Massachusetts General Hospital.

Recent updates

No updates

Editas Medicine, Inc. Stock Price

EDIT Share Price Performance

EDIT Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

Editas Medicine, Inc. Key Details

About EDIT

Recent EDIT News & Updates

Editas Medicine, Inc. Announces Appointment of Daniel Ory, M.D. as Chief Medical Officer, Effective September 8, 2026

Editas: Slow Progress Doesn't Mean No Progress For In-Vivo Gene Editor

Editas Medicine, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Recent updates

Editas Medicine, Inc. Competitors

MeiraGTx Holdings

Alumis

MannKind

Replimune Group